Cointime update: Novo Nordisk said its weight-loss drug Frehemgo has been approved in Saudi Arabia and is currently under review by the U.S. Food and Drug Administration and other regulators. The company disclosed the approval and the pending FDA review without giving a timeline for a U.S. decision. Frehemgo is Novo Nordisk’s weight-management treatment.
Novo Nordisk: Weight-Loss Drug Frehemgo Approved in Saudi Arabia, Under FDA Review
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
31m ago
House Democrats Target Trump Inner Circle in First Oversight Requests
50m ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
1h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal
2h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
2h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
2h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips